Shandong Boan Biotechnology Co., Ltd. (HKG:6955)
7.75
-0.01 (-0.13%)
At close: Feb 13, 2026
HKG:6955 Revenue
Shandong Boan Biotechnology had revenue of 393.41M CNY in the half year ending June 30, 2025, with 50.60% growth. This brings the company's revenue in the last twelve months to 756.78M, up 5.13% year-over-year. In the year 2024, Shandong Boan Biotechnology had annual revenue of 726.32M with 17.50% growth.
Revenue (ttm)
756.78M CNY
Revenue Growth
+5.13%
P/S Ratio
5.82
Revenue / Employee
1.06M CNY
Employees
714
Market Cap
4.82B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 726.32M | 108.19M | 17.50% |
| Dec 31, 2023 | 618.13M | 102.17M | 19.80% |
| Dec 31, 2022 | 515.96M | 357.26M | 225.11% |
| Dec 31, 2021 | 158.70M | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.01B |
| AIM Vaccine | 1.38B |
| BioDlink International Company | 1.17B |
| Ocumension Therapeutics | 595.79M |
| Medtide | 546.29M |
| Qyuns Therapeutics | 351.04M |
| Jacobio Pharmaceuticals Group | 220.66M |
| Mirxes Holding Company | 166.32M |